Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 3, 4 and 5 chronic kidney disease (not on dialysis)~* Hyperlipidemia requiring cholesterol lowering therapy~* Aged 18 to 80 years old~* Ability to provide informed consent~Exclusion Criteria:~* Patients requiring multiple cholesterol reducing agents~* Patients with neovascularization present, such as neoplasm, active wounds, or significant retinopathy~* Patients with contraindications or allergy to statins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).